Table 2.
Comparison of binary study outcomes for UF profiling and conventional UF treatment conditions.
| Outcome | Definition | Odds ratio (95% CI) |
|---|---|---|
| BP and cardiovascular outcomes | ||
| Intradialytic hypotensiona | Nadir systolic BP <90 mmHg | 1.2 (0.8, 1.7) |
| Troponin T risea | [(Post-HD - pre-HD troponin T) / pre-HD troponin T] ≥10% | 0.5 (0.2, 1.3) |
| Left ventricular GLS change | (Peak intradialytic stress GLS - baseline GLS) ≥2.5% | 0.8 (0.1, 4.4) |
| Volume-related outcomes | ||
| Plasma refillb | Hematocrit decrease by ≥0.5% | 0.2 (0.1, 0.9) |
| Target weight achievement | Post-HD weight <1 kg above or below prescribed target weight | 1.0 (0.7. 1.3) |
| Symptom outcomes | ||
| Cramping | Cramping during last 3 HD treatments ≥moderate severity | 0.9 (0.4, 2.1) |
| Nausea | Nausea or upset stomach during last 3 HD treatments ≥moderate severity | 0.7 (0.2, 2.2) |
| Vomiting | Vomiting or throwing up during last 3 HD treatments ≥moderate severity | 1.0 (0.1, 16.0) |
| Light-headedness | Dizziness or light-headedness during last 3 HD treatments ≥moderate severity | 0.2 (0.1, 0.9) |
| Racing heart | Racing heart or heart palpitations during last 3 HD treatments ≥moderate severity | 3.1 (0.3, 32.4) |
| Chest pain | Chest pain during last 3 HD treatments ≥moderate severity | 1.0 (0.2, 6.0) |
| Shortness of breath | Shortness of breath during last 3 HD treatments ≥moderate severity | 1.3 (0.3, 6.5) |
| Thirst | Thirst or dry mouth during last 3 HD treatments ≥moderate severity | 0.6 (0.3, 1.2) |
| Headache | Headache during last 3 HD treatments ≥moderate severity | 0.9 (0.4, 2.3) |
| Itching | Itching during last 3 HD treatments ≥moderate severity | 2.8 (1.2, 6.6) |
| Restless legs | Restless legs or difficulty keeping legs still during last 3 HD treatments ≥moderate severity | 1.2 (0.5, 2.6) |
| Tingling | Tingling or feeling of pins and needles during last 3 HD treatments ≥moderate severity | 0.6 (0.2, 2.4) |
| Time to recovery after HD | Response to question, “How long did it take you to recover after your last 3 HD treatments?” >12 hours | 1.1 (0.7, 1.8) |
| Other | ||
| Patient acceptance | Affirmative response to question, “If recommended by your kidney doctor, would you be willing to adopt the HD prescription you have received for the last 9 treatments?” | NRc |
Primary study outcome. All other listed outcomes were secondary or exploratory outcomes.
Plasma refill was measured by Crit-Line Monitors (Fresenius Medical Care North America, Waltham, MA). In treatments with plasma refill measurements, the UF time was set to 10 minutes shorter than the prescribed treatment run-time, and hematocrit values were measured at the time of UF termination and at the end of treatment. Plasma refill was deemed present if the hematocrit decreased by ≥0.5% from the termination of UF to the end of treatment.
Low event rate (non-acceptance=3 vs. acceptance=131) precludes accurate estimation of odds ratio (95% CI).
Abbreviations: BP, blood pressure; CI, confidence interval; GLS, global longitudinal strain; HD, hemodialysis; NR, not reported; UF, ultrafiltration.